These data demonstrated that tumor-specific inactivation of TBL1 sensitized pancreatic cancer to chemotherapeutic agents and diminished tumor growth in vivo in both therapeutic and preventive settings using two independent technical approaches. This evidence concerns the gene TBL1Y and familial pancreatic carcinoma.